Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company whose mission is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, announced today that it will hold a day opinion leaders (KOL’s Key Opinion Leader) to institutional investors and analysts on June 27, 2017 in New York, to comment on the results of the phase IIa in high blood pressure and present its next clinical trial in the United States.
Download the free guide
Boost your gains
Lionel Ségard, Chairman and ceo of Quantum Genomics, and Bruno Besse, Director-Medical, will present the data and analysis of the phase IIa study in high blood pressure and the next clinical trial across the Atlantic.
Doctors leading academics will be speaking during this event :
Keith C. Ferdinand, Professor of medicine at the Faculty of medicine of the Tulane University and former president of the National Forum for the Prevention of Heart Disease and strokes ;
Henry Black, a Professor of medicine associate clinician and a member of the section of cardiology of the Faculty of medicine of New York University and President emeritus of the American Society of Hypertension.
The event will continue with a round table moderated by Max Jacobs of Edison Investment Research.
Event : Quantum Genomics KOL & Investor Day
Date : Tuesday, 27 June 2017
Schedule : 11: 00 – 14: 00 (New York time)
Location : Le Parker Meridien, New York, NY
This conference will be recorded and will be available by webcast on the internet site of Quantum Genomics, www.quantum-genomics.com.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company whose mission is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, including high blood pressure and congestive heart failure.
Quantum Genomics is developing a new therapeutic approach based on inhibition of Aminopeptidase A in the brain (BAPAI – Brain Aminopeptidase A Inhibition), the result of more than twenty years of research in the laboratory “Central Neuropeptides and the Regulation of Fluid and Cardiovascular” (Collège de France, INSERM, CNRS, Université Paris Descartes), directed by Dr. Catherine Llorens-Cortes. This laboratory is associated with Quantum Genomics through a joint laboratory public/private, baptized CARDIOBAPAI, accredited by the French National Research Agency (ANR) since 2015.
Quantum Genomics, based in Paris and New York, is listed on the Alternext market in Paris (FR0011648971 – ALQGC).
Download the free guide
Boost your gains
